Related references
Note: Only part of the references are listed.New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates
Takehiro Ura et al.
VACCINE (2021)
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Emma C. Thomson et al.
CELL (2021)
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
Zhuoming Liu et al.
CELL HOST & MICROBE (2021)
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
Susanne H. Hodgson et al.
LANCET INFECTIOUS DISEASES (2021)
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
Constantinos Kurt Wibmer et al.
NATURE MEDICINE (2021)
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
Pablo Tebas et al.
ECLINICALMEDICINE (2021)
A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3
Youn Jin Choi et al.
CLINICAL CANCER RESEARCH (2020)
XCL1/Glypican-3 Fusion Gene Immunization Generates Potent Antitumor Cellular Immunity and Enhances Anti-PD-1 Efficacy
Kun Chen et al.
CANCER IMMUNOLOGY RESEARCH (2020)
A new coronavirus associated with human respiratory disease in China
Fan Wu et al.
NATURE (2020)
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Daniel Wrapp et al.
SCIENCE (2020)
Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks
Hossam M. Ashour et al.
PATHOGENS (2020)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Immunogenicity of a DNA vaccine candidate for COVID-19
Trevor R. F. Smith et al.
NATURE COMMUNICATIONS (2020)
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Bin Ju et al.
NATURE (2020)
Vaccines and Therapies in Development for SARS-CoV-2 Infections
David Wu et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Fabian Schmidt et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
SARS-CoV-2 Vaccine Development: Current Status
Gregory A. Poland et al.
MAYO CLINIC PROCEEDINGS (2020)
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Takuya Sekine et al.
CELL (2020)
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
Ching-Lin Hsieh et al.
SCIENCE (2020)
Cellular immune responses to covid-19 T cells could be valuable allies in pandemic control
Herb F. Sewell et al.
BMJ-BRITISH MEDICAL JOURNAL (2020)
The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development
Sana O. Alturki et al.
FRONTIERS IN IMMUNOLOGY (2020)
Immunological considerations for COVID-19 vaccine strategies
Mangalakumari Jeyanathan et al.
NATURE REVIEWS IMMUNOLOGY (2020)
The SARS-CoV-2 Vaccine Pipeline: an Overview
Wen-Hsiang Chen et al.
CURRENT TROPICAL MEDICINE REPORTS (2020)
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Alessandra Lopes et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Targeting Conventional Dendritic Cells to Fine-Tune Antibody Responses
Demo Yemane Tesfaye et al.
FRONTIERS IN IMMUNOLOGY (2019)
Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control
Natalia K. Botelho et al.
FRONTIERS IN IMMUNOLOGY (2019)
Targeting Influenza Virus Hemagglutinin to Xcr1+ Dendritic Cells in the Absence of Receptor-Mediated Endocytosis Enhances Protective Antibody Responses
Arnar Gudjonsson et al.
JOURNAL OF IMMUNOLOGY (2017)
CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses
Rodney A. Rosalia et al.
BIOMATERIALS (2015)
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Cornelia L. Trimble et al.
LANCET (2015)
Induction of Potent CD8 T Cell Cytotoxicity by Specific Targeting of Antigen to Cross-Presenting Dendritic Cells In Vivo via Murine or Human XCR1
Evelyn Hartung et al.
JOURNAL OF IMMUNOLOGY (2015)
Controlling immune responses by targeting antigens to dendritic cell subsets and B cells
Craig P. Chappell et al.
INTERNATIONAL IMMUNOLOGY (2014)
Targeting antigens to CD180 rapidly induces antigen-specific IgG, affinity maturation, and immunological memory
Jay W. Chaplin et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
DNA Vaccine that Targets Hemagglutinin to MHC Class II Molecules Rapidly Induces Antibody-Mediated Protection against Influenza
Gunnveig Grodeland et al.
JOURNAL OF IMMUNOLOGY (2013)
Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells
Annabell Bachem et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Selective Expression of the Chemokine Receptor XCR1 on Cross-presenting Dendritic Cells Determines Cooperation with CD8+ T Cells
Brigitte G. Dorner et al.
IMMUNITY (2009)
The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement
Irina Caminschi et al.
BLOOD (2008)
Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences
Agnete Brunsvik Fredriksen et al.
BLOOD (2007)
Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates
Gro Tunheim et al.
VACCINE (2007)
Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization
H Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
